Compare DexCom, Inc. (DXCM) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Xpeng Inc - ADR — how do they compare? DexCom, Inc. trades at $77.05 (market cap $28.06B), while Xpeng Inc - ADR trades at $14.14 (market cap $12.82B). The key difference: DexCom, Inc. is far larger — about 2.2× Xpeng Inc - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| DXCM | XPEV | |
|---|---|---|
Market Cap | $28.06B | $12.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $28.07 |
52-Week Low | $54.84 | $12.09 |
Enterprise Value | $27.03B | $14.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
XPeng (XPEV) trades at $14.255, up 6.7% on the day, showing bullish technical momentum. The company reported $76.72B revenue for 2025 with improving net margins (-1.49% vs -14.17% in 2024), though it remains unprofitable. Recent news highlights strong Q2 2026 deliveries of 103,295 vehicles and expansion into autonomous driving and robotics, positioning it as a physical AI leader. Analyst sentiment is predominantly bullish with 64.7% buy ratings.
The outlook is cautiously optimistic with revenue growth and margin improvement as key catalysts, but risks include persistent losses, intense EV competition, and macroeconomic pressures. Institutional support and new model launches provide upside potential, yet profitability remains the critical hurdle for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
